亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

成都云希化工有限公司  

美容肽,多肽,美容原料,定制肽,醫藥中間體

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:陳
  • 電話:19150309904
  • 郵件:aileen@youngshechem.com
  • 微信:19150309904
  • QQ:1398029096
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 棕櫚酰六肽-6/棕櫚酰六肽-14/Inyline
棕櫚酰六肽-6/棕櫚酰六肽-14/Inyline
單價 10.00 / g對比
銷量 暫無
發貨 四川成都市付款后3天內
庫存 10000g起訂1g
品牌 成都云希
外觀 白色粉末
功效 皮膚護理
過期 長期有效
更新 2021-07-05 16:42
 
詳細信息

Palmitoyl hexapeptide-6,Palmitoyl hexapeptide-14

1.Basic information:

INCI Name: Palmitoyl hexapeptide-6,Palmitoyl hexapeptide-14

Reference: InvisaSkin Matrix Rebuilder-O, Granactive Powder 168-EL

EINECS numer:

MSDS and COA: available for your reference, please contact us.

Purity: >95%

Source: synthetic

Grade: cosmetic

Stability: stable

Solubility: soluble in water

Odor: no

Delivery: promptly from stock

Appearance: white powder

 

2.Functions: Wrinkle treatment, anti-aging and face lift products in serum, gel cream and lotion forms. 

 

3.Description

Palmitoyl Hexapeptide-14 is a short bioactive peptide modified with palmitoyl for enhanced delivery and has proven to stimulate collagen production, stimulate proliferation of fibroblast cells and inhibit skin damaging MMPs. It helps reduce the appearance of fine lines and wrinkles, while eliminating dull and dry skin by rejuvenating and restoring tissue building processes. In independent studies Palmitoyl Hexapeptide-14 has been shown to be non-cytotoxic, non-mutagenic, non-irritating and non-sensitizing. 

©2025 成都云希化工有限公司 版權所有   技術支持:化工網   訪問量:41343  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |